Leerink Swann Upgrades Luminex (LMNX) to Outperform; Positive on GenturaDx and FDA Clearance of GPP
Tweet Send to a Friend
Leerink Swann upgraded Luminex (NASDAQ: LMNX) from Market Perform to Outperform with a price target range $26-$28.
Analyst, Dan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Dan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
